Emcure Pharmaceuticals Limited — Q1 FY26 earnings call

Call held 7 Aug 2025

Management summary

Emcure Pharmaceuticals reported a robust Q1 FY26, achieving its highest-ever quarterly profit of INR 215 crores, driven by strong growth across both domestic and international segments. The company's strategic focus on new initiatives, partnerships, and product innovation is yielding positive results, with significant margin expansion targeted over the next few years. Despite global funding challenges in ARV and potential US tariffs, Emcure remains insulated due to its low US market exposure.

Highlights

  • Revenue grew by 15.7% year-on-year to INR 2,101 crores.

  • EBITDA increased by 20.1% year-on-year to INR 404 crores.

  • PAT surged by 41% year-on-year, reaching a record high of INR 215 crores.

  • Domestic business expanded by 9.4% year-on-year to INR 995 crores, outperforming the industry.

  • International business demonstrated strong growth of 22% year-on-year, with Emerging Markets up 42%.

  • Gross margins stood at 61.8%, while EBITDA margins improved to 19.2% from 18.5% in Q1 FY24.

  • The company expanded its partnership with Sanofi for the diabetes segment, marketing key brands Amaryl and Cetapin.

  • Gross debt is currently INR 700 crores, with a revised target for debt reduction to zero within 1 to 1.5 years due to recent M&A.

Key financials

  1. Revenue ₹2,101 Cr +15.7%YoY
  2. EBITDA ₹404 Cr +20.1%YoY
  3. PAT ₹215 Cr +41%YoY
  4. Gross Margin 61.8%
  5. EBITDA Margin 19.2%
  6. Depreciation & Amortization ₹99 Cr
  7. Interest Cost ₹27 Cr
  8. Effective Tax Rate 26%

What they filed

Q1 FY27: revenue up 32.3%, net profit up 62.6% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue1,105 1,029 1,278 1,097 1,261 +14%1,418 +38%1,468 +15%1,451 +32%
EBITDA158 124 245 228 225 +42%300 +142%372 +52%340 +49%
Net profit87 50 140 123 118 +36%259 +418%234 +67%200 +63%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

Share of Revenue
₹3,206 Cr Total
  • International Business ₹1,106 Cr 34.5%
  • Domestic Business ₹995 Cr 31.0%
  • Europe ₹403 Cr 12.6%
  • Emerging Markets ₹360 Cr 11.2%
  • Canada ₹342 Cr 10.7%

Capital allocation

high confidence
  • Capex ₹350 Cr
    • Repair and maintenance capex ₹150 Cr
    • Capacity enhancements or product-specific capex requirements ₹200 Cr
    So, what we had been guiding to is that we expect annualized sort of capex spending in the range of about INR 350 crores a year. If you look at that, roughly about INR150 crores of that goes towards more repair and maintenance capex and about INR200-odd crores is in earmarked for. Some top-up investments for capacity enhancements or product-specific type capex requirements that we have.
  • Debt Gross ₹700 Cr
    Latest gross it is around INR 700 crores.
  • M&A Manx (product portfolio) Acquisition · Signed

    Will add to gross debt position and push out debt reduction timeline.

    one was the acquisition of product portfolio for Manx, which is going to be paid for in various milestones
  • M&A Zuventus (minority stake) Acquisition · Signed

    Will add to gross debt position and push out debt reduction timeline.

    as well as our recent announcement of acquiring the minority stake from Zuventus
  • Liquidity Cash ₹200 Cr
    Yes, INR200 crores.

Guidance & targets

Revenue

  • Overall Revenue Growth Revenue · ongoing · Medium confidence 2% more than industry growth
    As far as growth is concerned, I would like to have 2% more than the industry growth, whether we are talking about India or other markets, okay?

    — Satish Mehta

Profitability

  • EBITDA Margin Expansion Profitability · over this 4 to 5-year journey · High confidence 300 - 400 basis points
    we should continue the journey of increasing our margin profile by about 300 - 400 basis points over this 4 to 5-year journey

    — Vikas Thapar

  • EBITDA Margin Target Profitability · end of 5-year period · Medium confidence 23-24%
    Which means about 20% operating margins now over the 5-year period, it should be somewhere in the end of 23% 24%. That continues to be the goal and aspiration that we'll be working towards.

    — Vikas Thapar

Capex

  • Annualized Capex Spending Capex · a year · High confidence INR 350 crores
    So, what we had been guiding to is that we expect annualized sort of capex spending in the range of about INR 350 crores a year.

    — Vik Thapar

Debt

  • Debt Reduction to Zero Debt · FY26 · Low confidence by end of the current fiscal year
    we had guided on the debt was that barring any M&A, that should be approaching close to zero even by the end of the current fiscal year.

    — Vik Thapar

  • Debt Reduction to Zero (Revised) Debt · 1 to 1.5 years · Medium confidence at least 1 to 1.5 years going forward

    Previously by end of the current fiscal year → at least 1 to 1.5 years going forward

    these 2 initiatives will obviously add to our gross debt position which will probably push out our debt approaching zero by at least 1 to 1.5 years going forward.

    — Vik Thapar

Revenue Growth

  • Emerging Markets Growth Revenue Growth · this year · Medium confidence high teens to 20%
    I think for this year, what we had indicated is that for the emerging markets, we expect to grow in high teens to 20% around that.

    — Piyush Nahar

  • Domestic Business Growth from New Initiatives Revenue Growth · for the year · Medium confidence 1% or 2% additional growth
    I think what we had guided last time is that overall, we think that these 2 new initiatives should drive about 1% or 2% additional growth in our overall domestic business. So I think we're on track for delivering that for the year.

    — Vikas Thapar

  • Canada Operations Growth Rate Revenue Growth · as a whole · High confidence mid-teens growth rate
    Yes. So in Canada, I think the growth is sustainable. We had basically been guiding to sort of a mid-teens growth rate for the Canadian operation as a whole.

    — Vik Thapar

Product Approval

  • Asparaginase/Wet AMD Approval Product Approval · this financial year · High confidence at least one, if not both, should get approval
    So very hopeful that at least one, if not both, should get approval in this financial year.

    — Samit Mehta

Product Filing

  • Semaglutide Filing in Canada Product Filing · towards the end of this fiscal year · High confidence on track to file
    So I think we continue to be on track to file towards the end of this fiscal year.

    — Samit Mehta

What to watch in Q2 FY26

Asparaginase/Wet AMD Regulatory Approval

this financial year
Current Asparaginase dossier submitted to DCGI; Wet AMD clinical trial completing by Sep 2025
Target Approval for at least one of these products

Why it matters

Regulatory approvals for these pipeline products are crucial for future revenue streams and market entry.

So very hopeful that at least one, if not both, should get approval in this financial year.

Risks & concerns

  • Competition in Institutional Segment for Orofer FCM

    medium

    Competition at lower pricing in the institutional side for Orofer FCM is still a challenge.

    Management acknowledged

  • Global Funding Constraints for ARV Programs

    medium

    PEPFAR funding reduced from $3.5 billion to $2.9 billion, and funding from Americas also reduced, potentially impacting the ARV market.

    Management acknowledged

  • US Tariffs on Indian Exports

    low

    50% tariff announced by Trump administration, but Emcure's exposure to the US market is less than 3%, providing insulation.

    Management acknowledged

Q&A highlights

6 direct
India domestic growth breakup (volume, price, new launches) Direct
I think in terms of the price volume, volume would have been about 4% price about 4% and about a 1% to 2% of new launches that we have.

Provides granular detail on the drivers of domestic business growth.

Asked by Amey

Sanofi Diabetes portfolio sales contribution Direct
Sanofi would roughly be about INR 200 crores portfolio annualized. So, we'll get about 9 months of that in the year.

Quantifies the expected revenue contribution from the new Sanofi partnership for the current fiscal year.

Asked by Amey

Performance of Orofer FCM (prescription vs. institutional) Partial
I think on the prescription side now, we're seeing revival on growth. So this quarter, Orofer FCM grew in double digits for us. So that is doing well for us. I think where we are seeing still a bit more challenging is on the institution side, where some of the competition is still there at lower pricing.

Highlights the mixed performance of a key product, indicating competitive pressures in the institutional segment.

Asked by Amey

Ramp-up timeline for Amphotericin B launch in Europe Direct
However, in Europe, as we had told you over the last call, we got the approval under the DCP and each country typically takes anywhere between 3 to 5 months for its own national approval, which we expect to start from the end of this quarter. So I think the ramp-up in the second half of the year will be much higher than what we will see in H1.

Provides a clear timeline for the commercialization and revenue contribution from a key product in Europe.

Asked by Alankar

Emcure's strategy for sustained growth beyond 'me-too' products Direct
the reason why we have done well is because of science, innovation, and technology. And I take pride in telling everyone that as far as my company is concerned, it is in the forefront in launching new products and we're giving new products to the industry. ... for any company to survive and make headway, it has to focus on science and technology, and that's one area where we are committed

Clarifies management's long-term strategy focusing on innovation and new product development to drive sustainable growth.

Asked by Bharat Shah

Rationale for acquiring Sanofi diabetic portfolio and its link to future semaglutide launch Direct
As far as metabolics is concerned, this is a hook, Amaryl which will connect me to all the major consulting physicians and diabetologists with the help of that I feel that there will be profound effect on other products and will do well. ... with Amaryl, we get a good connect with the doctors and obviously, the same doctors are my potential prescribers to Semaglutide as well.

Reveals the strategic synergy of the Sanofi acquisition, positioning Emcure for future launches like semaglutide.

Asked by Gagan Thareja

Timeline for Asparaginase and wet AMD product approvals Direct
So for the Asparaginase we have already submitted our dossier to the DCGI and we're waiting to hear from them... And on the wet AMD also very positive in the sense that we should be completing our clinical trial by the end of September. So very hopeful that at least one, if not both, should get approval in this financial year.

Provides specific timelines for regulatory milestones for two important pipeline products.

Asked by Gagan Thareja

Impact of global funding constraints on ARV market and Lenacapavir's future Partial
PEPFAR funding is concerned to restore, but at the same time against $3.5 billion that they have been giving it has been reduced to $2.9 billion... Lenacapavir, it's going to be a game changer, but at the same time, there will always be a cost attached to it.

Highlights a significant external risk (reduced global funding) to the ARV segment and the cost implications for new, advanced therapies like Lenacapavir.

Asked by Gagan Thareja

3 min read 7 chapters

Detailed narrative

Strong Q1 FY26 Financial Performance

Emcure Pharmaceuticals delivered a robust performance in Q1 FY26, with revenue growing by 15.7% year-on-year to INR 2,101 crores. EBITDA saw a 20.1% increase, reaching INR 404 crores, while PAT surged by 41% year-on-year to a record INR 215 crores. The company's gross margins stood at 61.8%, and EBITDA margins improved to 19.2% from 18.5% in Q1 FY24, reflecting strong operating leverage and productivity gains.

Domestic Business Outperforms Industry

The domestic business grew faster than the industry, achieving a 9.4% year-on-year growth to INR 995 crores. This growth was broad-based, with strong performance across key therapies including Gynaec, Cardiac, Anti-infective, and Vitamins. New initiatives in Derma and consumer wellness are showing positive trends and are expected to become key growth drivers, contributing an additional 1-2% to overall domestic business growth for the year.

International Business Momentum and Strategic Expansion

International business recorded a strong 22% year-on-year growth, reaching INR 1,106 crores. Emerging Markets led this growth with a 42% increase to INR 360 crores, driven by new product approvals in target countries. Canada grew by 16.4% to INR 342 crores, and Europe saw a 12.8% growth to INR 403 crores. The company is strengthening its non-ARV segment with unique products and expects a significant ramp-up of Liposomal Amphotericin B in Europe in H2 FY26.

Strategic Partnerships and Product Pipeline

Emcure expanded its partnership with Sanofi for the diabetes segment, marketing and distributing oral diabetic portfolio brands like Amaryl and Cetapin from August 1st. This move is strategic for strengthening Emcure's presence in the metabolic diabeto segment and leveraging existing doctor relationships for future launches like Semaglutide. The company is also progressing with Asparaginase and wet AMD products, with at least one approval expected this financial year, and Semaglutide filing in Canada by year-end.

Margin Expansion and Operational Efficiency Targets

Management aims to expand its EBITDA margin profile by 300-400 basis points over the next 4-5 years, targeting 23-24% by the end of this period. This improvement will be driven by productivity gains in the Indian field force, scaling of the business, better utilization of manufacturing facilities, and a favorable product mix. The company expects to achieve approximately 100 basis points of operating cost improvement this year.

Capital Allocation and Debt Management

The company's gross debt stands at INR 700 crores. While an initial target was to bring debt close to zero by the end of the current fiscal year, recent acquisitions of a product portfolio for Manx and a minority stake in Zuventus will push out this timeline by at least 1 to 1.5 years. Annualized capex spending is projected at INR 350 crores, with INR 150 crores for maintenance and INR 200 crores for capacity enhancements and product-specific requirements. Cash and cash equivalents as of June 30, 2025, were INR 200 crores.

Insulation from US Market Risks

Emcure highlighted its insulation from potential US market risks, noting that its exposure to the US is less than 3%. This position provides a buffer against any adverse impacts from potential US tariffs on Indian exports, which management acknowledged as a concern in the broader industry context.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls